ISDA

Deposition Date 2014-07-07

Release Date 2015-05-27

Last Version Date 2023-11-08

Entry Detail

PDB ID:

4QT1

Keywords:

TRANSFERASE/TRANSFERASE INHIBITOR

Title:

JAK3 kinase domain in complex with 1-[(3S)-1-isobutylsulfonyl-3-piperidyl]-3-(5H-pyrrolo[2,3-b]pyrazin-2-yl)urea

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.40 Å

R-Value Free:

0.27

R-Value Work:

0.20

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Tyrosine-protein kinase JAK3
Gene (Uniprot):JAK3
Mutations:C1040S, C1048S
Chain IDs:A
Chain Length:314
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P52333 Pfam ID:PF07714 EC:2.7.10.2

Ligand Molecules

3C9

Primary Citation

Scaffold hopping towards potent and selective JAK3 inhibitors: discovery of novel C-5 substituted pyrrolopyrazines

De Vicente, J, Lemoine, R, Bartlett, M, Hermann, J.C, Hekmat-Nejad, M, Henningsen, R, Jin, S, Kuglstatter, A, Li, H, Lovey, A.J, Menke, J, Niu, L, Patel, V, Petersen, A, Setti, L, Shao, A, Tivitmahaisoon, P, Vu, M.D, Soth, M.Show

Bioorg.Med.Chem.Lett. 24 4969 4975 (2014)

PMID: 25262541 DOI: 10.1016/j.bmcl.2014.09.031

Abstact

The discovery of a novel series of pyrrolopyrazines as JAK inhibitors with comparable enzyme and cellular activity to tofacitinib is described. The series was identified using a scaffold hopping approach aided by structure based drug design using principles of intramolecular hydrogen bonding for conformational restriction and targeting specific pockets for modulating kinase activity.

Legend

Protein

Chemical

Disease

Primary Citation of related structures